Pzena Investment Management LLC Sells 38,267 Shares of Henry Schein, Inc. $HSIC

Pzena Investment Management LLC lowered its position in Henry Schein, Inc. (NASDAQ:HSIC) by 4.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 887,725 shares of the company’s stock after selling 38,267 shares during the period. Pzena Investment Management LLC’s holdings in Henry Schein were worth $67,094,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. MAI Capital Management increased its position in shares of Henry Schein by 7.5% in the 3rd quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after buying an additional 144 shares in the last quarter. Truist Financial Corp increased its position in shares of Henry Schein by 3.3% in the 3rd quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock valued at $368,000 after buying an additional 175 shares in the last quarter. HB Wealth Management LLC increased its position in shares of Henry Schein by 1.3% in the 4th quarter. HB Wealth Management LLC now owns 15,034 shares of the company’s stock valued at $1,136,000 after buying an additional 191 shares in the last quarter. Czech National Bank boosted its stake in Henry Schein by 0.8% in the 4th quarter. Czech National Bank now owns 26,386 shares of the company’s stock worth $1,994,000 after purchasing an additional 206 shares during the period. Finally, Jain Global LLC boosted its stake in Henry Schein by 2.0% in the 3rd quarter. Jain Global LLC now owns 10,662 shares of the company’s stock worth $708,000 after purchasing an additional 207 shares during the period. Institutional investors own 96.62% of the company’s stock.

Insider Activity

In other Henry Schein news, Director Kurt P. Kuehn sold 2,844 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the completion of the sale, the director directly owned 15,420 shares in the company, valued at $1,217,563.20. This trade represents a 15.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Mark E. Mlotek sold 5,925 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total transaction of $478,740.00. Following the sale, the executive vice president owned 80,554 shares of the company’s stock, valued at $6,508,763.20. This trade represents a 6.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 105,911 shares of company stock valued at $8,574,982. Company insiders own 0.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on HSIC shares. JPMorgan Chase & Co. upped their target price on shares of Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Wall Street Zen lowered shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Wells Fargo & Company upped their target price on shares of Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th. Barrington Research set a $97.00 price objective on shares of Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, Leerink Partners restated a “market perform” rating on shares of Henry Schein in a research note on Monday, March 9th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $86.83.

Henry Schein Stock Performance

Shares of NASDAQ HSIC opened at $73.50 on Friday. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $89.29. The stock has a 50 day moving average of $74.39 and a 200-day moving average of $75.63. The company has a market capitalization of $8.37 billion, a P/E ratio of 22.21, a P/E/G ratio of 1.84 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same period in the previous year, the company posted $1.15 EPS. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities research analysts predict that Henry Schein, Inc. will post 5.31 EPS for the current year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.